Henry Schein, Inc. HSIC SPXR3KPHARMA
Company Overview
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Why Investors Should Care
Trades at a P/E of 25.1, below the sector median of 25.6.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $13.18B (+4.0% YoY); net profit $398.00M.
- Trailing 12 Months Year-on-year growth — revenue +6.7%, earnings +17.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 1.4%, profit CAGR -9.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1.40% |
| 1 Year: | 6.70% |
Compounded Profit Growth
| 5 Years: | -9.56% |
| 1 Year: | 17.10% |
Stock Price Performance
| 1 Year: | +24.66% |
| 6 Months: | +9.95% |
| 3 Months: | +0.62% |
| 1 Month: | +1.12% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)51.74 · Neutral
P/E of 25.07 is below the sector median of 25.61 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -9.6% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HSIC Henry Schein, Inc. SPXR3KPHARMA | 86.00 | 25.07 | $9.80B | 0.00% | 9.49% | 8.85% | 1.40% | -9.56% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Apr 2017 | Jul 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Apr 2023 | Jul 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 2.27B | 2.32B | 2.36B | 2.47B | 2.36B | 2.45B | 9.99B | 2.67B | 2.43B | 1.68B | 2.84B | 3.17B | 2.92B | 2.97B | 3.18B | 3.18B | 3.03B | 3.07B | 3.06B | 3.10B | 3.16B | 3.17B | 3.14B | 3.17B | - | 3.24B | 3.34B | 3.44B | 3.37B | 3.46B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.22B | 2.31B | 2.37B | 2.30B | 2.36B |
| Gross Profit | 748.91M | 799.28M | 777.84M | 801.47M | 787.67M | 859.49M | 822.92M | 839.17M | 836.05M | 900.96M | 719.13M | 718.33M | 722.36M | 750.93M | 751.69M | 767.43M | 761.17M | 810.60M | 746.01M | 454.27M | 754.27M | 859.71M | 891.00M | 891.00M | 912.00M | 973.00M | 945.00M | 914.00M | 966.00M | 975.00M | 995.00M | 1.01B | 1.02B | 993.00M | - | 1.02B | 1.03B | 1.06B | 1.07B | 1.10B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 842.00M | 828.00M | 877.00M | 876.00M | 901.00M |
| Operating Income | 188.88M | 200.69M | 176.19M | 180.68M | 200.72M | 213.98M | 193.97M | 210.66M | 213.55M | 241.19M | 162.24M | 157.11M | 123.27M | 158.00M | 172.44M | 162.29M | 187.20M | 196.33M | 173.87M | -7.43M | 187.67M | 181.20M | 230.00M | 210.00M | 211.00M | 244.00M | 220.00M | 211.00M | 175.00M | 201.00M | 200.00M | 150.00M | 159.00M | 157.00M | - | 174.00M | 198.00M | 186.00M | 194.00M | 200.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 235.00M | 252.00M | 241.00M | 270.00M | 264.00M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 38.00M | 38.00M | 39.00M | 39.00M | 43.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 121.00M | 134.00M | 133.00M | 150.00M | 137.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 31.00M | 28.00M | 32.00M | 38.00M | 34.00M |
| Net Income | 127.73M | 129.95M | 113.75M | 120.10M | 133.71M | 139.22M | 140.75M | 136.06M | 138.03M | -8.54M | 111.53M | 110.64M | 90.77M | 117.78M | 109.78M | 114.53M | 140.56M | 330.61M | 130.26M | -10.80M | 141.70M | - | 166.00M | 156.00M | 162.00M | 181.00M | 160.00M | 150.00M | 121.00M | 140.00M | 137.00M | 93.00M | 104.00M | 99.00M | - | 86.00M | 101.00M | 101.00M | 107.00M | 94.00M |
| Diluted EPS | 1.52 | 1.56 | 0.69 | 0.73 | 0.82 | 0.86 | 0.88 | 0.86 | 0.87 | -0.06 | 0.72 | 0.72 | 0.59 | 0.77 | 0.78 | 0.78 | 0.91 | 2.25 | 0.91 | -0.08 | 0.99 | 0.99 | 1.16 | 1.10 | 1.15 | 1.30 | 1.16 | 1.09 | 0.91 | 1.06 | 1.05 | 0.72 | 0.80 | 0.78 | - | 0.70 | 0.84 | 0.85 | 0.92 | 0.82 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.38B | 6.54B | 7.53B | 8.53B | 8.94B | 9.56B | 10.37B | 10.63B | 11.57B | 8.88B | 9.42B | 9.99B | 10.12B | - | 12.65B | 12.34B | 12.67B | 13.18B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.82B | 8.48B | 8.66B | 9.08B |
| Gross Profit | 1.87B | 1.92B | 2.17B | 2.42B | 2.51B | 2.66B | 2.91B | 3.01B | 3.23B | 2.75B | 2.91B | 3.09B | 2.82B | - | 3.83B | 3.86B | 4.02B | 4.11B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.95B | 3.17B | 3.29B | 3.35B |
| Operating Income | 419.29M | 464.08M | 521.13M | 582.15M | 618.96M | 677.05M | 715.14M | 733.97M | 771.57M | 669.76M | 600.62M | 718.26M | 535.00M | - | 878.00M | 695.00M | 731.00M | 758.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 950.00M | 851.00M | 912.00M | 964.00M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 35.00M | 87.00M | 131.00M | 150.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 721.00M | 542.00M | 513.00M | 533.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 170.00M | 120.00M | 128.00M | 126.00M |
| Net Income | 239.46M | 311.15M | 325.79M | 367.66M | 388.08M | 431.55M | 466.08M | 479.06M | 506.78M | 406.30M | 535.88M | 694.73M | 404.00M | - | 538.00M | 416.00M | 390.00M | 398.00M |
| Diluted EPS | 2.63 | 3.44 | 3.49 | 3.97 | 4.32 | 4.93 | 5.44 | 2.85 | 3.10 | 2.57 | 3.49 | 4.65 | 2.82 | - | 3.91 | 3.16 | 3.05 | 3.27 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 3.60B | 3.84B | 4.55B | 4.74B | 5.33B | 5.62B | 6.14B | 6.53B | 6.81B | 7.86B | 8.50B | 7.15B | 7.77B | 8.48B | 8.61B | 10.57B | 10.22B | 11.21B |
| Total Equity | 1.67B | 1.77B | 2.16B | 2.41B | 2.43B | 2.61B | 2.79B | 2.81B | 2.88B | 2.79B | 2.81B | 2.96B | 3.00B | 3.35B | 3.42B | 3.45B | 3.65B | 3.39B | 3.25B |
| Cash & Equivalents | 247.59M | 369.57M | 471.15M | 150.35M | 147.28M | 122.08M | 188.62M | 89.47M | 72.09M | 62.38M | 174.66M | 80.21M | - | 421.19M | 118.00M | 117.00M | 171.00M | 122.00M | 156.00M |
| Long Term Debt | - | - | 243.37M | 395.31M | 363.52M | - | - | - | - | - | - | - | - | - | 822.00M | 1.05B | - | - | - |
| Total Liabilities | - | - | 1.50B | 1.83B | 1.90B | 2.28B | 2.34B | 2.76B | 3.08B | 3.35B | 4.21B | 4.65B | 3.23B | 3.46B | 3.81B | 3.94B | 5.42B | 5.38B | 6.42B |
| Current Liabilities | - | - | 1.08B | 1.17B | 1.27B | 1.47B | 1.55B | 1.78B | 2.15B | 2.32B | 2.83B | 3.22B | 2.04B | 2.28B | 2.31B | 2.22B | 2.68B | 2.80B | 3.23B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 384.78M | 398.03M | 395.48M | 554.62M | 408.10M | - | - | 615.50M | 642.58M | 545.51M | 684.71M | 654.09M | 599.00M | 710.00M | 602.00M | 500.00M | 848.00M | 712.00M |
| Investing Cash Flow | -168.01M | -98.59M | -387.62M | -193.22M | -269.60M | - | - | -260.03M | -316.42M | -342.28M | -192.95M | -424.37M | -115.00M | -677.00M | -276.00M | -1.14B | -430.00M | -400.00M |
| Financing Cash Flow | -87.97M | -197.68M | -330.64M | -357.21M | -170.60M | - | - | -348.03M | -327.34M | -112.55M | -603.78M | -215.98M | -187.00M | -333.00M | -315.00M | 701.00M | -510.00M | -188.00M |
| Share Buybacks | 82.79M | 0 | 57.73M | 200.00M | 299.88M | 300.25M | 299.99M | 299.85M | 550.02M | 450.00M | 200.00M | 525.00M | 74.00M | 401.00M | 485.00M | 250.00M | 385.00M | 850.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 29.4% | 29.3% | 28.8% | 28.3% | 28.0% | 27.8% | 28.1% | 28.3% | 27.9% | 30.9% | 30.9% | 31.0% | 27.8% | - | 30.3% | 31.3% | 31.7% | 31.1% |
| Operating Margin % | 6.6% | 7.1% | 6.9% | 6.8% | 6.9% | 7.1% | 6.9% | 6.9% | 6.7% | 7.5% | 6.4% | 7.2% | 5.3% | - | 6.9% | 5.6% | 5.8% | 5.7% |
| Net Margin % | 3.8% | 4.8% | 4.3% | 4.3% | 4.3% | 4.5% | 4.5% | 4.5% | 4.4% | 4.6% | 5.7% | 7.0% | 4.0% | - | 4.3% | 3.4% | 3.1% | 3.0% |
| ROE % | 13.5% | 14.4% | 13.5% | 15.1% | 14.8% | 15.5% | 16.6% | 16.6% | 18.1% | 14.5% | 18.1% | 23.2% | 12.1% | - | 15.6% | 11.4% | 11.5% | 12.3% |
| ROCE % | - | 16.8% | 15.4% | 16.8% | 16.0% | 16.6% | 16.4% | 16.7% | 17.2% | 13.3% | 11.4% | 14.0% | 9.7% | - | 13.8% | 8.8% | 9.9% | 9.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kohlberg Kravis Roberts & Co. L.P. | 14.04% | 15.65M | $1.31B |
| 2 | FMR, LLC | 6.78% | 7.55M | $634.60M |
| 3 | Blackrock Inc. | 6.30% | 7.02M | $590.14M |
| 4 | Artisan Partners Limited Partnership | 5.80% | 6.47M | $543.33M |
| 5 | Vanguard Capital Management LLC | 5.69% | 6.35M | $533.18M |
| 6 | JPMORGAN CHASE & CO | 3.90% | 4.34M | $364.85M |
| 7 | State Street Corporation | 3.86% | 4.31M | $361.69M |
| 8 | Vanguard Portfolio Management LLC | 3.71% | 4.13M | $347.25M |
| 9 | American Century Companies Inc | 3.10% | 3.46M | $290.44M |
| 10 | Dimensional Fund Advisors LP | 3.05% | 3.39M | $285.15M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HSIC
Henry Schein Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxOckNSZXdDZVFSa0JiX1J4TjBPbGlYMEdJVmpJVEhFTnhhRklCSW1WdUpfZ0lON1R5NW5ua0doQ2l4Q2FCX3I4VWNaaVZaUklQZXNJZlkxWjltSFR0OFdKaE5wV3FfUWZEc0JKTzBqemlZM1VoZjRoRkxibVREVk5OMFhIY0dVa3B5VUtWaz…
Unpacking Q2 Earnings: Henry Schein (NASDAQ:HSIC) In The Context Of Other Dental Equipment & Technology Stocks - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMimwJBVV95cUxPV2tJNndVbm9Nd09Xb3NEYTRWQVFvX19JNnk1QllBU0xpTjV5WVFCUnlweTYxUXo0YjlpaUQxbWRXZHRocjBLV2VkOFl2Q3ctTlhDS0FRZGZlV0tBanV3UFhiMS14VkFPM3l4d2Y4WF9YVHB0V0JjOFpkM21KS2ZyYjZGQXlWNFh1SWpGcj…
HSIC Surpasses Q2 Earnings and Revenue Estimates, Stock Climbs - August 4, 2026 - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOd0F2M3JXNEZaRWZsT19CQks3M29FcVYzTHc2RTJTRW02NmxjUVZxaUVRQ2NCcjd0TE50WGVSTUlaNGRXc2VDNU1XYzV5LTdmRlc3ZkNlZU5qNmJ3R3ZFZVpQdlhnd1R1SUFMSjRUeGhjd3ZIaGZteHF6dzg5RldoN0I3akxCNGxsU1l4Un…
HSIC Jan 2027 70.000 call (HSIC270115C00070000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE80TElmSnlwRUVQVVdrV1ZiMlRSb3pLS2NHclZuMF9oUW4zUmRTajZfcDBaRmJQaUhnNUVHWVQ4N1lqM1E1cFlFZVh4bXRjbDRxY1U3eTZwZG1IX0s3bmFkRDNpNUlaUQ?oc=5" target="_blank">HSIC Jan 2027 70.000 call (HS…
Henry Schein Inc. stock underperforms Monday when compared to competitors - MarketWatch
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNSTg2S2dUalZ3NGl5UFBjdW41M3l2UmYza0kxc0JEMjlxdDVHVzZkUUo1ZW90V2NNVUhrTUlNTWQ1ekpuamNmZWdldkxHVC05RUd5Q1lBZHZRVG9PVEFiS18xSXlsUnczcmpCOUxVQjg0U1Bfcmc4bEc5SlNXdVlrUW43dGFOeXNMbUp1OG…
Should Value Investors Buy Henry Schein (HSIC) Stock? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNdnhVMGRuUk5QQzFscDltb0dQVUJObnY4RG1QVTA0SmE5QWprYldMVG8zZGZUbVFmQ1kzZ2NtYWVKcm0yYW9kYXpHSVZ5QklCclQ5bUFGWTNYNFRHRGFYSXA2RERNX3ZxNzVhbmc2bnhsSGVFWnhncGNQOWdYempnZnZUeDBoTDFoaGtPQ2…
HSIC — Frequently Asked Questions
What is the current share price of Henry Schein, Inc. (HSIC)?
As of 2026-10-22 16:30 PDT, Henry Schein, Inc. (HSIC) trades at $86.00 on NasdaqGS. Its 52-week range is $62.03 to $90.86.
What is the market capitalisation of HSIC?
Henry Schein, Inc. (HSIC) has a market capitalisation of $9.80B on NasdaqGS.
What is the P/E ratio of HSIC?
HSIC trades at a trailing price-to-earnings (P/E) ratio of 25.07. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 3.01.
What is the return on equity (ROE) of HSIC?
HSIC has a return on equity (ROE) of 8.85%. Its return on capital employed (ROCE) is 9.49%.
Is HSIC a good stock to buy?
This page provides a data-driven analysis of Henry Schein, Inc. (HSIC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.